Clinical trials can be extremely beneficial in learning more about various diseases, as well as the safety, efficacy, and tolerability of potential treatments. According to a news release from global pharmaceutical company Vifor Pharma (“Vifor”), the first patient was enrolled in the Phase 2a SCD-202 clinical trial. During the trial, researchers will evaluate Vamifeport (VIT-2763) for patients with sickle cell disease (SCD).

Vamifeport

Vamifeport (VIT-2763) is a ferroportin inhibitor, which is administered orally. Normally, ferroportin plays a role in iron transport and acquisition within the body. However, in patients with sickle cell disease, too much iron could enter into the bloodstream. Vamifeport stops this from occurring and, in turn, stops the formation of too much abnormal hemoglobin. Researchers believe this could prevent some of the inflammation and red blood cell destruction often seen in SCD. Outside of SCD, researchers are also evaluating Vamifeport as a potential therapy for patients with beta-thalassemia. So far, this therapy has received Orphan Drug designations in both Europe and the United States.

In the burgeoning SCD-202 trial, researchers will evaluate Vamifeport for adults with SCD. Altogether, 25 patients will enroll. The study aims to focus on whether the treatment reduces incidences of hemolysis (red blood cell destruction).